Biotoxtech바이오톡스텍
086040 · KOSDAQ · ₩086040 · 바이오톡스텍
₩2,110▲ ₩30 (1.44%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩47B | ₩41B | ₩33B | ₩37B | ₩34B |
| Cost of sales | ₩41B | ₩39B | ₩31B | ₩25B | ₩22B |
| Gross profit | ₩5.9B | ₩2.6B | ₩1.9B | ₩12B | ₩12B |
| Operating income | −₩4.8B | −₩8.9B | −₩8.2B | ₩800M | ₩4.2B |
| Net income | −₩1.6B | −₩13B | −₩9B | ₩1.5B | ₩7B |
| Net income to shareholders | ₩1.2B | −₩6.4B | −₩4.9B | ₩2.7B | ₩7.1B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩132B | ₩136B | ₩147B | ₩126B | ₩91B |
| Current assets | ₩49B | ₩59B | ₩65B | ₩49B | ₩38B |
| Cash and equivalents | ₩19B | ₩11B | ₩27B | ₩13B | ₩19B |
| Total liabilities | ₩100B | ₩102B | ₩99B | ₩81B | ₩49B |
| Current liabilities | ₩85B | ₩82B | ₩75B | ₩60B | ₩46B |
| Borrowings | ₩38B | ₩42B | ₩44B | ₩35B | ₩27B |
| Total equity | ₩32B | ₩35B | ₩48B | ₩44B | ₩42B |
| Shareholders' equity | ₩40B | ₩40B | ₩52B | ₩44B | ₩41B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩6.6B | −₩7.1B | −₩16B | −₩1.3B | ₩4.3B |
| Capital spending | ₩2.1B | ₩2B | ₩4.5B | ₩31B | ₩7.6B |
| Free cash flow | ₩4.5B | −₩9.1B | −₩21B | −₩32B | −₩3.3B |
Consolidated where available. Amounts in won.
Also known as: Biotoxtech / 바이오톡스텍 / 086040 / KRX:086040
Source: KRX statistical information